

# The Executive Office of Health & Human Services

## Pharmacy and Therapeutics Committee Meeting Minutes



Tuesday, April 4, 2023

8:00 AM

EOHHS, Virks Building  
3 West Road, Cranston, RI 02920

### P & T Members Present:

Todd Brothers, PharmD  
Nickolai Morin, PharmD  
Tracey Taviera, PharmD  
Matt Salisbury, MD  
Rick Wagner, MD

### Absent:

Greg Allen, MD  
Dezere Hodish, Assistant Director Financial and Contract Management (EOHHS)  
Karen Mariano, RPh (Gainwell Technologies)  
Bill Quirk, RPh

### Others Present:

Ann Bennett, MHSA (Gainwell Technologies)  
Kelly Leighton (Gainwell Technologies)  
Joe Morasutti, PharmD (Gainwell Technologies)  
Jerry Fingerut, MD, Medical Director, (EOHHS)  
Kathryn Novak, RPh (Magellan Medicaid Administration)

**The meeting was called to order by the Chairperson once a quorum was in attendance – 8:11am.** Chairperson Tracey Taviera called the meeting to order and asked for introductions of the committee and those supporting the meeting. The September 20, 2022 and December 13, 2022, draft meeting minutes were approved.

### Public testimony included the following speakers and topics.

Follow up information should be sent to [ann.bennett2@gainwelltechnologies.com](mailto:ann.bennett2@gainwelltechnologies.com) for distribution to the committee.

P & T Speakers	Affiliation	Topic
No Speakers for this meeting		

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee. MMA reminded the audience that Medicaid covers all medications as long as the manufacturer has signed a contract with CMS even if it is not on the PDL. FFS RI Medicaid is secondary on many claims therefore the PDL compliance in some classes is not always the best due to other insurance paying the majority of the claim which allows it to bypass PDL rules. Also, informed the audience that this meeting and the Preferred Drug List is strictly for FFS RI Medicaid, not any of the Managed Care Organizations. MMA Addressed the shortage issue of certain drugs stating FFS RI Medicaid makes allowances for other options.

Therapeutic Categories		Comments & Discussion	Vote: Yes	Vote: No	Abstain	Motion
<b>Blood Modifying Agents</b>	Antihyperuricemics	No recommended changes to the current preferred agents	5	0	0	Passed
	Bile Salts	No recommended changes to the current preferred agents	5	0	0	Passed
	Colony Stimulating Factors	It was recommended to move Fylnetra to a preferred agent and move Granix syringe and Nyvepria to non-preferred agents	5	0	0	Passed
	Erythropoiesis Stimulating Proteins	No recommended changes to the current preferred agents	5	0	0	Passed
	Phosphate Binders	No recommended changes to the current preferred agents – Remove Renagel (no longer available)	5	0	0	Passed
	Potassium Binders	No recommended changes to the current preferred agents	5	0	0	Passed
<b>Endocrine Agents</b>	Androgenic Agents	No recommended changes to the current preferred agents	5	0	0	Passed
	Bone Resorption Inhibitors	No recommended changes to the current preferred agents	5	0	0	Passed
	Contraceptives, Other	It was recommended to move Twirla and Zafemy to preferred agents and move Xulane to a non-preferred agent.	5	0	0	Passed
	Enzyme Replacement, Gauchers Disease	No recommended changes to the current preferred agents	5	0	0	Passed
	Glucagon Agents	It was recommended to move Glucagon Emergency Kit (Lily) to preferred and move Glucagon Emergency Kit (Fresenius) to non-preferred.	5	0	0	Passed
	Growth Hormones	It was recommended to move Nutropin AQ Pen to preferred and move Norditropin Pen to non-preferred.	5	0	0	Passed
	<u>Hypoglycemics</u>					

	<i>Alpha-Glucosidase Inhibitors</i>	No recommended changes to the current preferred agents	5	0	0	Passed
	<i>Incretin Mimetics/Enhancers</i>	It was recommended to move Trulicity to non-preferred. However, a motion made to keep Trulicity as preferred due to supply availability issues. Revisit in 6 months when updated ADA guidelines are finalized.	5	0	0	Passed keeping Trulicity as preferred – committee will review in 6 months
	<i>Insulins</i>	It was recommended to move insulin glargine pen and insulin glargine vial to preferred agents.	5	0	0	Passed
	<i>Meglitinides</i>	No recommended changes to the current preferred Agents	5	0	0	Passed
	<i>Metformins</i>	It was recommended to move Riomet Solution to a preferred agent.	5	0	0	Passed
	<i>SGLT2s</i>	No recommended changes to the current preferred agents	5	0	0	Passed
	<i>Sulfonylureas</i>	No recommended changes to the current preferred agents	5	0	0	Passed
	<i>Thiazolidinediones</i>	No recommended changes to the current preferred agents	5	0	0	Passed
	Pancreatic Enzymes	No recommended changes to the current preferred agents	5	0	0	Passed
	Pituitary Suppressive Agents, LHRH	No recommended changes to the current preferred agents	5	0	0	Passed
	Progestins for Cachexia	No recommended changes to the current preferred agents	5	0	0	Passed
	Weight Management Agents	No recommended changes to the	4	1	0	Passed adding

		current preferred agents. However, a motion was made to add Contrave due to the oral route of administration. Revisit in 6 months when updated ADA guidelines are finalized.				Contrave as preferred - Committee will review in 6 months.
<b>GI Agents</b>	Antiemetic Agents	No recommended changes to the current preferred agents	5	0	0	Passed
	GI Motility, Chronic	No recommended changes to the current preferred agents	5	0	0	Passed
	H. Pylori Agents	No recommended changes to the current preferred agents	5	0	0	Passed
	Proton Pump Inhibitors	It was recommended to move Dexilant to a preferred agent.	5	0	0	Passed
	Ulcerative Colitis Agents	It was recommended to move mesalamine (Canasa) (rectal) and SFRowasa (rectal) to preferred agents and move Canasa (rectal) and Rowasa (rectal) to non-preferred agents.	5	0	0	Passed

#### Next Meeting

Tuesday, June 6, 2023

#### Meeting schedule for the year:

June 6, 2023

September 12, 2023

December 12, 2023

#### Adjournment

The meeting adjourned at 9:15 AM